Show simple item record

dc.contributor.authorPrice, David B.
dc.contributor.authorBosnic-Anticevich, Sinthia
dc.contributor.authorPavord, Ian D.
dc.contributor.authorRoche, Nicolas
dc.contributor.authorHalpin, David M. G.
dc.contributor.authorBjermer, Leif
dc.contributor.authorUsmani, Omar S.
dc.contributor.authorBrusselle, Guy
dc.contributor.authorMing, Simon Wan Yau
dc.contributor.authorRastogi, Sarang
dc.date.accessioned2019-08-22T08:40:08Z
dc.date.available2019-08-22T08:40:08Z
dc.date.issued2019-08-21
dc.identifier.citationPrice , D B , Bosnic-Anticevich , S , Pavord , I D , Roche , N , Halpin , D M G , Bjermer , L , Usmani , O S , Brusselle , G , Ming , S W Y & Rastogi , S 2019 , ' Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations ' , Clinical and Translational Allergy , vol. 9 , no. 1 , 41 . https://doi.org/10.1186/s13601-019-0282-7en
dc.identifier.issn2045-7022
dc.identifier.otherPURE: 146922732
dc.identifier.otherPURE UUID: dd9de81a-7638-4851-aebf-f274f9dc9ca0
dc.identifier.otherRIS: urn:F7257ADE5C6BF072D2EE659FAC0A66DF
dc.identifier.otherRIS: Price2019
dc.identifier.otherScopus: 85070956142
dc.identifier.otherPubMed: 31452870
dc.identifier.otherMendeley: 9f1d4e29-a974-3024-a729-805a9ced0c67
dc.identifier.otherWOS: 000483502800001
dc.identifier.urihttp://hdl.handle.net/2164/12749
dc.identifier.urihttp://www.scopus.com/inward/record.url?scp=85070956142&partnerID=8YFLogxKen
dc.identifier.urihttp://www.mendeley.com/research/association-elevated-fractional-exhaled-nitric-oxide-concentration-blood-eosinophil-count-severe-asten
dc.descriptionAcknowledgements The authors thank Gokul Gopalan and Sadia Halim for their contributions to the development of a poster based on the findings of this study, which was presented at the British Thoracic Society (BTS) Winter Meeting, 6–8 December 2017, London, United Kingdom. Editorial support was provided by Michelle Rebello, PhD, of Cactus Communications (Mumbai, India) and Michael A. Nissen, ELS, of AstraZeneca (Gaithersburg, MD, USA) in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). This support was fully funded by AstraZeneca. Funding This study was funded by AstraZeneca. Availability of data and materials Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.en
dc.format.extent18
dc.language.isoeng
dc.relation.ispartofClinical and Translational Allergyen
dc.rights© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectAsthmaen
dc.subjectblood eosinophilsen
dc.subjectexhaled airway markersen
dc.subjectnitric oxideen
dc.subjectExhaled airway markersen
dc.subjectBlood eosinophilsen
dc.subjectNitric oxideen
dc.subjectMULTICENTERen
dc.subjectMEPOLIZUMABen
dc.subjectGUIDELINESen
dc.subjectADULTSen
dc.subjectINHALED CORTICOSTEROIDSen
dc.subjectPERSISTENT ASTHMAen
dc.subjectCAREen
dc.subjectR Medicine (General)en
dc.subjectPulmonary and Respiratory Medicineen
dc.subjectImmunology and Allergyen
dc.subjectImmunologyen
dc.subjectSupplementary Dataen
dc.subject.lccR1en
dc.titleAssociation of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbationsen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.description.versionsupplementary_dataen
dc.identifier.doihttps://doi.org/10.1186/s13601-019-0282-7
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85070956142&partnerID=8YFLogxKen
dc.identifier.urlhttp://www.mendeley.com/research/association-elevated-fractional-exhaled-nitric-oxide-concentration-blood-eosinophil-count-severe-asten
dc.identifier.vol9en
dc.identifier.iss1en


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record